NCT04506619View on ClinicalTrials.gov

Safety and Efficacy Outcomes Following Previously Administered Short-Term Treatment With SHP607 in Extremely Premature Infants

TerminatedOBSERVATIONAL
Enrollment

26

Participants

Timeline

Start Date

September 9, 2020

Primary Completion Date

August 5, 2022

Study Completion Date

August 5, 2022

Conditions
Retinopathy of Prematurity (ROP)Intraventricular HemorrhageBronchopulmonary DysplasiaChronic Lung Disease of Prematurity
Interventions
OTHER

No Intervention

This is a non-interventional study.

Trial Locations (8)

16147

Istituto G Gaslini Ospedale Pediatrico IRCCS - INCIPIT - PIN, Genova

31100

Presidio Ospedaliero Di Treviso Ca' Foncello, Treviso

39216

University of Mississippi Medical Center, Jackson

46601

Memorial Hospital of South Bend, South Bend

50134

Azienda Ospedaliera Universitaria Careggi, Florence

39216-4505

University of Mississippi Medical Center, Jackson

08901

Robert Wood Johnson Medical School, New Brunswick

KT16 0PZ

Ashford and St. Peter's Hospitals NHS Trust - St. Peter*s Hospital, Chertsey

Sponsors

Lead Sponsor

Oak Hill Bio Ltd
All Listed Sponsors
lead

Oak Hill Bio Ltd

INDUSTRY

NCT04506619 - Safety and Efficacy Outcomes Following Previously Administered Short-Term Treatment With SHP607 in Extremely Premature Infants | Biotech Hunter | Biotech Hunter